Jeffrey Robert Ajer Net Worth

The estimated Net Worth of Jeffrey Robert Ajer is at least $22.1 Million dollars as of 2 May 2024. Mr Ajer owns over 5,000 units of Biomarin Pharmaceutical stock worth over $5,660,506 and over the last 12 years he sold BMRN stock worth over $15,347,605. In addition, he makes $1,051,257 as Exec. VP & Chief Commercial Officer at Biomarin Pharmaceutical.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Ajer BMRN stock SEC Form 4 insiders trading

Mr has made over 74 trades of the Biomarin Pharmaceutical stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of BMRN stock worth $414,550 on 2 May 2024.

The largest trade he's ever made was exercising 49,000 units of Biomarin Pharmaceutical stock on 25 January 2023 worth over $3,322,690. On average, Mr trades about 2,644 units every 34 days since 2012. As of 2 May 2024 he still owns at least 66,767 units of Biomarin Pharmaceutical stock.

You can see the complete history of Mr Ajer stock trades at the bottom of the page.

Mr. Jeffrey Robert Ajer biography

Jeffrey Robert Ajer is the Exec. VP & Chief Commercial Officer at Biomarin Pharmaceutical.

What is the salary of Mr Ajer?

As the Exec. VP & Chief Commercial Officer of Biomarin Pharmaceutical, the total compensation of Mr Ajer at Biomarin Pharmaceutical is $1,051,257. There are 7 executives at Biomarin Pharmaceutical getting paid more, with Jean-Jacques Bienaime having the highest compensation of $18,405,900.

How old is Mr Ajer?

Mr Ajer is 59, he's been the Exec. VP & Chief Commercial Officer of Biomarin Pharmaceutical since . There are 13 older and 8 younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.

What's Mr Ajer's mailing address?

Jeffrey's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL, CA, 94901.

Insiders trading at Biomarin Pharmaceutical

Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy, and Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.

What does Biomarin Pharmaceutical do?

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment

Complete history of Mr Ajer stock trades at Biomarin Pharmaceutical and Nektar Therapeutics

Biomarin Pharmaceutical executives and stock owners

Biomarin Pharmaceutical executives and other stock owners filed with the SEC include:

• Jean-Jacques Bienaime,
  Chairman of the Board, Chief Executive Officer
• Henry Fuchs,
  President - Worldwide Research & Development
• Jeff Ajer,
  Executive Vice President, Chief Commercial Officer
• Jean-Jacques Bienaime M.B.A., MBA,
  Chairman & CEO
• G. Eric Davis,
  Executive Vice President, General Counsel, Secretary
• Dr. Henry J. Fuchs,
  Pres of Worldwide R&D
• Dr. C. Greg Guyer Ph.D.,
  CTO and Exec. VP of Global Manufacturing & Technical Operations
• Jeffrey Robert Ajer,
  Exec. VP & Chief Commercial Officer
• Brian R. Mueller,
  Exec. VP of Fin. & CFO
• Richard Meier,
  Lead Independent Director
• Elaine Heron,
  Independent Director
• Robert Hombach,
  Independent Director
• Alan Lewis,
  Independent Director
• Michael Grey,
  Independent Director
• V. Bryan Lawlis,
  Independent Director
• David Pyott,
  Independent Director
• Dennis Slamon,
  Independent Director
• Willard Dere,
  Independent Director
• Elizabeth Anderson,
  Independent Director
• Lon Cardon,
  Chief Scientific Strategy Officer
• Andrea Acosta,
  Chief Accounting Officer, Group Vice President
• C. Greg Guyer,
  Chief Technical Officer, Executive Vice President of Global Manufacturing, Technical Operations
• Brian Mueller,
  Chief Financial Officer, Executive Vice President
• Dr. Brinda Balakrishnan M.D., Ph.D.,
  Group VP of Corp. & Bus. Devel.
• Philip Lo Scalzo,
  Sr. VP & Chief Compliance Officer
• George Eric Davis,
  Exec. VP, Gen. Counsel & Sec.
• Traci McCarty,
  VP of Investor Relations
• Andrea L. Acosta,
  Group VP & Chief Accounting Officer
• Daniel K Spiegelman,
  EVP, Chief Financial Officer
• Athena Countouriotis,
  Director
• Mark J Enyedy,
  Director
• Barbara W. Bodem,
  Director
• Robert Baffi,
  President, Global Mfg/Tech Ops
• Cristin Hubbard,
  EVP, Chief Commercial Officer
• Kathryn E Falberg,
  Director
• William D Young,
  Director
• Pierre Lapalme,
  Director
• Jeffrey Landau,
  Sr. Vice President, Admin.
• Gwynn Williams,
  Director
• Steve Aselage,
  SVP, Global Commercial Ops
• Christopher M Starr,
  Sr. VP, Scientific Operations
• Franz L Cristiani,
  Director
• Jeffrey H Cooper,
  Chief Financial Officer
• Joseph Iii Klein,
  Director
• Emil D Kakkis,
  SVP, Business Operations
• Kenneth Bate,
  Director
• Mark Wood,
  VP, Human Resources
• John Urquhart,
  Director
• Erich Sager,
  Director
• Stuart J Swiedler,
  SVP, Clinical Affairs
• Fredric D Price,
  Chief Executive Officer
• Vijay B Samant,
  Director
• Maykin Ho,
  Director
• Mark J Alles,
  Director
• Erin Burkhart,
  GVP, Chief Accounting Officer
• Alexander Hardy,
  Chief Executive Officer